Form 4: Disc Medicine Chief Medical Officer Executes Stock Transactions Under 10b5-1 Plan

Disc Medicine's Chief Medical Officer, William Jacob Savage, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• William Jacob Savage, Chief Medical Officer of Disc Medicine, Inc., engaged in several transactions involving the company's stock on November 15, 2024.
• These transactions included the exercise of stock options to acquire 9,158 shares at $9.86 per share and the subsequent sale of 9,158 shares.
• The sales were executed in multiple transactions at weighted average prices of $59.5369, $60.1582 and $61.1 per share.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on July 18, 2024.
• Following these transactions, Mr. Savage directly owns 40,405 shares of Disc Medicine stock and 36,034 stock options.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sentiment is neutral to slightly positive due to the use of a 10b5-1 plan.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which is a common practice for insiders to avoid accusations of trading on non-public information.

Risks

• The sale of shares by a key executive could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders who execute stock transactions. The use of a 10b5-1 plan is a common practice to avoid insider trading accusations.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Disc Medicine.
• Similar filings are regularly made by executives at companies like Vertex Pharmaceuticals and BioMarin Pharmaceutical, reflecting routine stock transactions under pre-arranged plans.
• The reported prices are within the expected range for a company of this size and stage in the biotechnology industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive could be perceived negatively, but the use of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Disc Medicine, stock transactions, Form 4, insider trading, Rule 10b5-1, stock options, Chief Medical Officer, William Jacob Savage